clinical trials and observational studies show efficacy and tolerability of adalimumab in the management of immune mediated inflammatory diseases.

anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab / Armuzzi A; Lionetti P; Blandizzi C; Caporali R; Chimenti S; Cimino L; Gionchetti P; Girolomoni G; Lapadula G; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Cimaz R. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - STAMPA. - 27:(2014), pp. 11-32. [10.1177/03946320140270S102]

anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab

LIONETTI, PAOLO;CIMAZ, ROLANDO
2014

Abstract

clinical trials and observational studies show efficacy and tolerability of adalimumab in the management of immune mediated inflammatory diseases.
2014
27
11
32
Armuzzi A; Lionetti P; Blandizzi C; Caporali R; Chimenti S; Cimino L; Gionchetti P; Girolomoni G; Lapadula G; Marchesoni A; Marcellusi A; Mennini FS; ...espandi
1a - Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/867698
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 48
social impact